Cost-efficient high-throughput HLA typing by MiSeq amplicon sequencing7thSpace Interactive (press release)A close match of the HLA alleles between donor and recipient is an important prerequisite for successful unrelated hematopoietic stem cell transpl…
Illumina, LabCorp Ink Multi-Year Deal – Analyst BlogNASDAQLast week, ILMN announced plans to enter emerging markets in mid-2014 by launching a human leukocyte antigen (HLA) typing product, developed using its NGS platform. The HLA typing assays that LH…
|
Illumina Sketches Strategy to Push NGS into Reproductive Health, Disease …
GenomeWeb HLA typing represents another $300 million market opportunity, according to the company. Illumina has already started to penetrate some of these new markets, as evidenced by a shift in its customer base. Over the last five years, Illumina’s revenue … |
Illumina, LabCorp Ink Multi-Year DealZacks.comLast week, ILMN announced plans to enter emerging markets in mid-2014 by launching a human leukocyte antigen (HLA) typing product, developed using its NGS platform. The HLA typing assays that LH will develo…
Illumina Targets HLA Typing, Forensics with MiSeq; Unveils NeoPrep; Details …GenomeWebIllumina announced a new automated sequencing library prep system called NeoPrep last week, along with plans to sell customized versions of the MiSeq system for for…
|
Illumina to Supply LabCorp with NGS, Microarray Instruments for LDT …
GenomeWeb “The Illumina next-generation sequencing platform gives LabCorp the flexibility to develop a wide range of molecular tests,” Mark Brecher, LabCorp’s chief medical officer, said in a statement. “The HLA typing assays we are developing on Illumina’s … |
|
Illumina to Supply LabCorp with NGS and Microarray Instruments
GenomeWeb “The Illumina next-generation sequencing platform gives LabCorp the flexibility to develop a wide range of molecular tests,” Mark Brecher, LabCorp’s chief medical officer, said in a statement. “The HLA typing assays we are developing on Illumina’s … |
|
Illumina Signs Master Supply Agreement to Provide Next-Generation …
Investor’s Business Daily “The HLA typing assays we are developing on Illumina’s family of NGS platforms will provide physicians with the ability to more accurately match bone marrow donors to recipients.” “We are excited to support LabCorp’s ability to offer more NGS-based … |
|
Illumina Inc.: Illumina Signs Master Supply Agreement to Provide Next …
The Wall Street Transcript “The HLA typing assays we are developing on Illumina’s family of NGS platforms will provide physicians with the ability to more accurately match bone marrow donors to recipients.” “We are excited to support LabCorp’s ability to offer more NGS-based … |
|
Illumina (ILMN), Lab Corp (LH) Enter Multi-Year Supply Agreement
StreetInsider.com (subscription) “The HLA typing assays we are developing on Illumina’s family of NGS platforms will provide physicians with the ability to more accurately match bone marrow donors to recipients.” “We are excited to support LabCorp’s ability to offer more NGS-based … |